Yasmin Tahira, Adnan Sadia, Younis Muhammad Numair, Fatima Arzoo, Shahid Abubaker
Consultant Nuclear Medicine, Department of Nuclear Medicine and PET Imaging, Institute of Nuclear Medicine and Oncology Lahore (INMOL), Lahore, Pakistan.
Consultant Oncologist, Department of Radiation and Oncology, Institute of Nuclear Medicine and Oncology Lahore (INMOL), Lahore, Pakistan.
Dose Response. 2021 Dec 14;19(4):15593258211062775. doi: 10.1177/15593258211062775. eCollection 2021 Oct-Dec.
The role of Iodine-131 therapy is well established as an adjuvant therapy and for thyroid remnant ablation in differentiated thyroid cancer (DTC); however controversy still exists regarding its appropriate dose. Purpose of this study was to compare the effectiveness of low-dose and high-dose Iodine-131 ablation therapies in low- and intermediate-risk PTC patients. Eighty-four patients were divided equally into Group I: Ablated with high dose of Iodine-131 and Group II: Ablated with low dose of Iodine-131. Iodine-131 WBS, serum levels and USG neck of all patients were performed at first presentation, 6 months, 1 year, and 2 years follow up. Results are as follows: Group I: 64%, 72%, and 76% intermediate-risk patients were disease free at the follow up intervals of 6 months, 1 year, and 2 years, respectively. Similarly 70%, 82%, and 82% low-risk patients were disease free at above mentioned intervals. Group II: 56%, 60%, and 64% were disease free among intermediate-risk patients while percentage of disease free low-risk patients was 70%, 76%, and 76% at follow up intervals. Low dose of radioactive Iodine-131 was found as effective as high dose in thyroid remnant ablation of PTC patients.
碘-131治疗作为分化型甲状腺癌（DTC）的辅助治疗和甲状腺残余组织消融的作用已得到充分确立；然而，关于其合适剂量仍存在争议。本研究的目的是比较低剂量和高剂量碘-131消融疗法对低危和中危乳头状甲状腺癌（PTC）患者的疗效。84例患者被平均分为两组：第一组用高剂量碘-131进行消融，第二组用低剂量碘-131进行消融。在初次就诊时、随访6个月、1年和2年时，对所有患者进行碘-131全身显像（WBS）、血清学检查和颈部超声检查。结果如下：第一组：在随访6个月、1年和2年时，分别有64%、72%和76%的中危患者无疾病。同样地，在上述随访期间，分别有70%、82%和82%的低危患者无疾病。第二组：中危患者中无疾病的比例分别为56%、60%和64%，而低危患者在随访期间无疾病的比例分别为70%、76%和76%。结果发现，低剂量放射性碘-131在PTC患者的甲状腺残余组织消融中与高剂量同样有效。
